1
|
Leidi F, Boari GEM, Scarano O, Mangili B, Gorla G, Corbani A, Accordini B, Napoli F, Ghidelli C, Archenti G, Turini D, Saottini M, Guarinoni V, Ferrari-Toninelli G, Manzoni F, Bonetti S, Chiarini G, Malerba P, Braglia-Orlandini F, Bianco G, Faustini C, Agabiti-Rosei C, De Ciuceis C, Rizzoni D. Comparison of the characteristics, morbidity and mortality of COVID-19 between first and second/third wave in a hospital setting in Lombardy: a retrospective cohort study. Intern Emerg Med 2022; 17:1941-1949. [PMID: 35809152 PMCID: PMC9521559 DOI: 10.1007/s11739-022-03034-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 06/12/2022] [Indexed: 01/08/2023]
Abstract
Coronavirus disease 2019 (COVID-19) represents a major health problem in terms of deaths and long-term sequelae. We conducted a retrospective cohort study at Montichiari Hospital (Brescia, Italy) to better understand the determinants of outcome in two different COVID-19 outbreaks. A total of 634 unvaccinated patients admitted from local emergency room to the Internal Medicine ward with a confirmed diagnosis of SARS-CoV-2 infection and a moderate-to-severe COVID-19 were included in the study. A group of 260 consecutive patients during SARS-CoV-2 first wave (from February to May 2020) and 374 consecutive patients during SARS-CoV-2 2nd/3rd wave (from October 2020 to May 2021) were considered. Demographic data were not significantly different between waves, except a lower prevalence of female sex during first wave. Mortality was significantly higher during the 1st wave than in the following periods (24.2% vs. 11%; p < 0.001). Time from symptoms onset to hospital admission was longer during first wave (8 ± 6 vs. 6 ± 4 days; p < 0.001), while in-hospital staying was significantly shorter (10 ± 14 vs. 15 ± 11 days; p < 0.001). Other significant differences were a larger use of corticosteroids and low-molecular weight heparin as well less antibiotic prescription during the second wave. Respiratory, bio-humoral and X-ray scores were significantly poorer at the time of admission in first-wave patients. After a multivariate regression analysis, C-reactive protein and procalcitonin values, % fraction of inspired oxygen on admission to the Internal Medicine ward and length of hospital stay and duration of symptoms were the strongest predictors of outcome. Concomitant anti-hypertensive treatment (including ACE-inhibitors and angiotensin-receptor blockers) did not affect the outcome. In conclusion, our data suggest that earlier diagnosis, timely hospital admission and rational use of the therapeutic options reduced the systemic inflammatory response and were associated to a better outcome during the 2nd/3rd wave.
Collapse
Affiliation(s)
- Francesca Leidi
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | | | - Ottavio Scarano
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Benedetta Mangili
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Giulia Gorla
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Andrea Corbani
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Beatrice Accordini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Federico Napoli
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Chiara Ghidelli
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Giulia Archenti
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Daniele Turini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
| | - Michele Saottini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
| | - Vittoria Guarinoni
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
| | | | - Francesca Manzoni
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
| | - Silvia Bonetti
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Giulia Chiarini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Paolo Malerba
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Federico Braglia-Orlandini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Gianluca Bianco
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Cristina Faustini
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Claudia Agabiti-Rosei
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Carolina De Ciuceis
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy
| | - Damiano Rizzoni
- Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy.
| |
Collapse
|
2
|
Boari GEM, Bonetti S, Braglia-Orlandini F, Chiarini G, Faustini C, Bianco G, Santagiuliana M, Guarinoni V, Saottini M, Viola S, Ferrari-Toninelli G, Pasini G, Bonzi B, Desenzani P, Tusi C, Malerba P, Zanotti E, Turini D, Rizzoni D. Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study. High Blood Press Cardiovasc Prev 2021; 28:373-381. [PMID: 33909284 PMCID: PMC8080190 DOI: 10.1007/s40292-021-00454-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 04/15/2021] [Indexed: 01/08/2023] Open
Abstract
The aim of the study was to assess the short-term consequences of SARS-CoV-2-related pneumonia, also in relation to radiologic/laboratory/clinical indices of risk at baseline. This prospective follow-up cohort study included 94 patients with confirmed COVID-19 admitted to a medical ward at the Montichiari Hospital, Brescia, Italy from February 28th to April 30th, 2020. Patients had COVID-19 related pneumonia with respiratory failure. Ninety-four patients out of 193 survivors accepted to be re-evaluated after discharge, on average after 4 months. In ¼ of the patients an evidence of pulmonary fibrosis was detected, as indicated by an altered diffusing capacity of the lung for carbon monoxide (DLCO); in 6-7% of patients the alteration was classified as of moderate/severe degree. We also evaluated quality of life thorough a structured questionnaire: 52% of the patients still lamented fatigue, 36% effort dyspnea, 10% anorexia, 14% dysgeusia or anosmia, 31% insomnia and 21% anxiety. Finally, we evaluated three prognostic indices (the Brixia radiologic score, the Charlson Comorbidity Index and the 4C mortality score) in terms of prediction of the clinical consequences of the disease. All of them significantly predicted the extent of short-term lung involvement. In conclusion, our study demonstrated that SARS-CoV-2-related pneumonia is associated to relevant short-term clinical consequences, both in terms of persistence of symptoms and in terms of impairment of DLCO (indicator of a possible development of pulmonary fibrosis); some severity indices of the disease may predict short-term clinical outcome. Further studies are needed to ascertain whether such manifestations may persist long-term.
Collapse
Affiliation(s)
- Gianluca E. M. Boari
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Silvia Bonetti
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Federico Braglia-Orlandini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Giulia Chiarini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Cristina Faustini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Gianluca Bianco
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Marzia Santagiuliana
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Vittoria Guarinoni
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Michele Saottini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Sara Viola
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | | | - Giancarlo Pasini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Bianca Bonzi
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Paolo Desenzani
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Claudia Tusi
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Paolo Malerba
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Eros Zanotti
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Daniele Turini
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
| | - Damiano Rizzoni
- Division of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia Italy
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy
| |
Collapse
|
3
|
De Ciuceis C, Agabiti-Rosei C, Rossini C, Caletti S, Coschignano MA, Ferrari-Toninelli G, Ragni G, Cappelli C, Cerudelli B, Airò P, Scarsi M, Tincani A, Porteri E, Rizzoni D. Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients. High Blood Press Cardiovasc Prev 2018; 25:369-378. [PMID: 30203268 DOI: 10.1007/s40292-018-0279-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 09/03/2018] [Indexed: 01/30/2023] Open
Abstract
INTRODUCTION Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection. AIM To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density. METHODS Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger. RESULTS Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation. CONCLUSIONS Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect.
Collapse
Affiliation(s)
- Carolina De Ciuceis
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Claudia Agabiti-Rosei
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Claudia Rossini
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Stefano Caletti
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Maria Antonietta Coschignano
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | | | - Giorgio Ragni
- Division of Medicine, Spedali Civili di Brescia, Gardone Val Trompia, Italy
| | - Carlo Cappelli
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Bruno Cerudelli
- Division of Medicine, Spedali Civili di Brescia, Gardone Val Trompia, Italy
| | - Paolo Airò
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Mirko Scarsi
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Angela Tincani
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Enzo Porteri
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy
| | - Damiano Rizzoni
- Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy.
- Division of Medicine, Istituto Clinico Città di Brescia, Brescia, Italy.
| |
Collapse
|
4
|
Bettinsoli P, Ferrari-Toninelli G, Bonini SA, Guarienti M, Cangelosi D, Varesio L, Memo M. Favorable prognostic role of tropomodulins in neuroblastoma. Oncotarget 2018; 9:27092-27103. [PMID: 29930753 PMCID: PMC6007461 DOI: 10.18632/oncotarget.25491] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 05/07/2018] [Indexed: 12/14/2022] Open
Abstract
Neuroblastoma is a pediatric tumor of the sympatoadrenal lineage of the neural crest characterized by high molecular and clinical heterogeneity, which are the main causes of the poor response to standard multimodal therapy. The identification of new and selective biomarkers is important to improve our knowledge on the mechanisms of neuroblastoma progression and to find the targets for innovative cancer therapies. This study identifies a positive correlation among tropomodulins (TMODs) proteins expression and neuroblastoma progression. TMODs bind the pointed end of actin filaments, regulate polymerization and depolymerization processes modifying actin cytoskeletal dynamic and influencing neuronal development processes. Expression levels of TMODs genes were analyzed in 17 datasets comprising different types of tumors, including neuroblastoma, and it was demonstrated that high levels of tropomodulin1 (TMOD1) and tropomodulin 2 (TMOD2) correlate positively with high survival probability and with favorable clinical and molecular characteristics. Functional studies on neuroblastoma cell lines, showed that TMOD1 knockin induced cell cycle arrest, cell proliferation arrest and a mature functional differentiation. TMOD1 overexpression was responsible for particular cell morphology and biochemical changes which directed cells towards a neuronal favorable differentiation profile. TMOD1 downregulation also induced cell proliferation arrest but caused the loss of mature cell differentiation and promoted the development of neuroendocrine cellular characteristics, delineating an aggressive and unfavorable tumor behavior. Overall, these data indicated that TMODs are favorable prognostic biomarkers in neuroblastoma and we believe that they could contribute to unravel a new pathophysiological mechanism of neuroblastoma resistance contributing to the design of personalized therapeutics opportunities.
Collapse
Affiliation(s)
- Paola Bettinsoli
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Brescia, Italy
| | - Giulia Ferrari-Toninelli
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Brescia, Italy
| | - Sara Anna Bonini
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Brescia, Italy
| | - Michela Guarienti
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Brescia, Italy
| | - Davide Cangelosi
- Laboratory of Molecular Biology, Giannina Gaslini Institute, Genova, Italy
| | - Luigi Varesio
- Laboratory of Molecular Biology, Giannina Gaslini Institute, Genova, Italy
| | - Maurizio Memo
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Brescia, Italy
| |
Collapse
|
5
|
Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, Bonini SA. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Horm Mol Biol Clin Investig 2018; 36:/j/hmbci.ahead-of-print/hmbci-2018-0013/hmbci-2018-0013.xml. [PMID: 29601300 DOI: 10.1515/hmbci-2018-0013] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Accepted: 03/02/2018] [Indexed: 12/26/2022]
Abstract
The use of different natural and/or synthetic preparations of Cannabis sativa is associated with therapeutic strategies for many diseases. Indeed, thanks to the widespread diffusion of the cannabinoidergic system in the brain and in the peripheral districts, its stimulation, or inhibition, regulates many pathophysiological phenomena. In particular, central activation of the cannabinoidergic system modulates the limbic and mesolimbic response which leads to food craving. Moreover, cannabinoid agonists are able to reduce inflammatory response. In this review a brief history of cannabinoids and the protagonists of the endocannabinoidergic system, i.e. synthesis and degradation enzymes and main receptors, will be described. Furthermore, the pharmacological effects of cannabinoids will be outlined. An overview of the involvement of the endocannabinoidergic system in neuroinflammatory and metabolic pathologies will be made. Finally, particular attention will also be given to the new pharmacological entities acting on the two main receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), with particular focus on the neuroinflammatory and metabolic mechanisms involved.
Collapse
Affiliation(s)
- Andrea Mastinu
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy
| | - Marika Premoli
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy
| | - Giulia Ferrari-Toninelli
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy.,Istituto Clinico Città di Brescia, Brescia, Italy
| | - Simone Tambaro
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden
| | - Giuseppina Maccarinelli
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy
| | - Maurizio Memo
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy
| | - Sara Anna Bonini
- Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, Italy
| |
Collapse
|
6
|
Bettinsoli P, Ferrari-Toninelli G, Bonini SA, Prandelli C, Memo M. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma. BMC Cancer 2017; 17:352. [PMID: 28525978 PMCID: PMC5438559 DOI: 10.1186/s12885-017-3340-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 05/11/2017] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Neuroblastoma is the most common extracranial solid malignancy in childhood, responsible for 15% of all pediatric cancer deaths. It is an heterogeneous disease that does not always respond to classical therapy; so the identification of new and specific molecular targets to improve existing therapy is needed. We have previously demonstrated the involvement of the Notch pathway in the onset and progression of neuroblastoma. In this study we further investigated the role of Notch signaling and identified Delta-like 1 (DLL1) as a novel molecular target in neuroblastoma cells with a high degree of MYCN amplification, which is a major oncogenic driver in neuroblastoma. The possibility to act on DLL1 expression levels by using microRNAs (miRNAs) was assessed. METHODS DLL1 mRNA and protein expression levels were measured in three different neuroblastoma cell lines using quantitative real-time PCR and Western Blot analysis, respectively. Activation of the Notch pathway as a result of increased levels of DLL1 was analyzed by Immunofluorescence and Western Blot methods. In silico tools revealed the possibility to act on DLL1 expression levels with miRNAs, in particular with the miRNA-34 family. Neuroblastoma cells were transfected with miRNA-34 family members, and the effect of miRNAs transfection on DLL1 mRNA expression levels, on cell differentiation, proliferation and apoptosis was measured. RESULTS In this study, the DLL1 ligand was identified as the Notch pathway component highly expressed in neuroblastoma cells with MYCN amplification. In silico analysis demonstrated that DLL1 is one of the targets of miRNA-34 family members that maps on chromosome regions that are frequently deregulated or deleted in neuroblastoma. We studied the possibility to use miRNAs to target DLL1. Among all miRNA-34 family members, miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels, to arrest cell proliferation and to induce neuronal differentiation in malignant neuroblastoma cells. CONCLUSIONS Targeted therapies have emerged as new strategies for cancer treatment. This study identified the Notch ligand DLL1 as a novel and attractive molecular target in childhood neuroblastoma and its results could help to devise a targeted therapy using miRNAs.
Collapse
Affiliation(s)
- P Bettinsoli
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy.
| | - G Ferrari-Toninelli
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy
| | - S A Bonini
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy
| | - C Prandelli
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy
| | - M Memo
- Department of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy
| |
Collapse
|
7
|
Bonini SA, Mastinu A, Maccarinelli G, Mitola S, Premoli M, La Rosa LR, Ferrari-Toninelli G, Grilli M, Memo M. Cortical Structure Alterations and Social Behavior Impairment in p50-Deficient Mice. Cereb Cortex 2016; 26:2832-49. [PMID: 26946128 PMCID: PMC4869818 DOI: 10.1093/cercor/bhw037] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Alterations in genes that regulate neurodevelopment can lead to cortical malformations, resulting in malfunction during postnatal life. The NF-κB pathway has a key role during neurodevelopment by regulating the maintenance of the neural progenitor cell pool and inhibiting neuronal differentiation. In this study, we evaluated whether mice lacking the NF-κB p50 subunit (KO) present alterations in cortical structure and associated behavioral impairment. We found that, compared with wild type (WT), KO mice at postnatal day 2 present an increase in radial glial cells, an increase in Reelin protein expression levels, in addition to an increase of specific layer thickness. Moreover, adult KO mice display abnormal columnar organization in the somatosensory cortex, a specific decrease in somatostatin- and parvalbumin-expressing interneurons, altered neurite orientation, and a decrease in Synapsin I protein levels. Concerning behavior, KO mice, in addition to an increase in locomotor and exploratory activity, display impairment in social behaviors, with a reduction in social interaction. Finally, we found that risperidone treatment decreased hyperactivity of KO mice, but had no effect on defective social interaction. Altogether, these data add complexity to a growing body of data, suggesting a link between dysregulation of the NF-κB pathway and neurodevelopmental disorders pathogenesis.
Collapse
Affiliation(s)
- Sara Anna Bonini
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Andrea Mastinu
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Giuseppina Maccarinelli
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Stefania Mitola
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Marika Premoli
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Luca Rosario La Rosa
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | | | - Mariagrazia Grilli
- Laboratory of Neuroplasticity, Department of Pharmaceutical Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Maurizio Memo
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| |
Collapse
|
8
|
La Rocca R, Ferrari-Toninelli G, Patanè S. Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure. Int J Cardiol 2014; 177:57-60. [PMID: 25499340 DOI: 10.1016/j.ijcard.2014.09.095] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 09/20/2014] [Indexed: 12/14/2022]
Affiliation(s)
- Roberto La Rocca
- Resp. U.O. Medicina Generale, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Giulia Ferrari-Toninelli
- Medico in formazione specialistica in Farmacologia Medica, Università degli Studi di Brescia, Italy
| | - Salvatore Patanè
- Cardiologia Ospedale San Vincenzo, Taormina (Me) Azienda Sanitaria Provinciale di Messina, 98039 Taormina, Messina, Italy. patane-@libero.it
| |
Collapse
|
9
|
Bonini SA, Ferrari-Toninelli G, Montinaro M, Memo M. Notch signalling in adult neurons: a potential target for microtubule stabilization. Ther Adv Neurol Disord 2013; 6:375-85. [PMID: 24228073 DOI: 10.1177/1756285613490051] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Cytoskeletal dysfunction has been proposed during the last decade as one of the main mechanisms involved in the aetiology of several neurodegenerative diseases. Microtubules are basic elements of the cytoskeleton and the dysregulation of microtubule stability has been demonstrated to be causative for axonal transport impairment, synaptic contact degeneration, impaired neuronal function leading finally to neuronal loss. Several pathways are implicated in the microtubule assembly/disassembly process. Emerging evidence is focusing on Notch as a microtubule dynamics regulator. We demonstrated that activation of Notch signalling results in increased microtubule stability and changes in axonal morphology and branching. By contrast, Notch inhibition leads to an increase in cytoskeleton plasticity with intense neurite remodelling. Until now, several microtubule-binding compounds have been tested and the results have provided proof of concept that microtubule-binding agents or compounds with the ability to stabilize microtubules may have therapeutic potential for the treatment of Alzheimer's disease and other neurodegenerative diseases. In this review, based on its key role in cytoskeletal dynamics modulation, we propose Notch as a new potential target for microtubule stabilization.
Collapse
Affiliation(s)
- Sara Anna Bonini
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | | | | | | |
Collapse
|
10
|
Bonini SA, Ferrari-Toninelli G, Maccarinelli G, Bettinsoli P, Montinaro M, Memo M. Cytoskeletal Protection: Acting on Notch to Prevent Neuronal Dysfunction. NEURODEGENER DIS 2013; 13:93-5. [DOI: 10.1159/000354230] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 07/07/2013] [Indexed: 11/19/2022] Open
|
11
|
Buizza L, Cenini G, Lanni C, Ferrari-Toninelli G, Prandelli C, Govoni S, Buoso E, Racchi M, Barcikowska M, Styczynska M, Szybinska A, Butterfield DA, Memo M, Uberti D. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One 2012; 7:e29789. [PMID: 22242180 PMCID: PMC3252333 DOI: 10.1371/journal.pone.0029789] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Accepted: 12/05/2011] [Indexed: 11/18/2022] Open
Abstract
In order to study oxidative stress in peripheral cells of Alzheimer's disease (AD) patients, immortalized lymphocytes derived from two peculiar cohorts of patients, referring to early onset AD (EOSAD) and subjects harboured AD related mutation (ADmut), were used. Oxidative stress was evaluated measuring i) the typical oxidative markers, such as HNE Michel adducts, 3 Nitro-Tyrosine residues and protein carbonyl on protein extracts, ii) and the antioxidant capacity, following the enzymatic kinetic of superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GRD). We found that the signs of oxidative stress, measured as oxidative marker levels, were evident only in ADmut but not in EOSAD patients. However, oxidative imbalance in EOSAD as well as ADmut lymphocytes was underlined by a reduced SOD activity and GRD activity in both pathological groups in comparison with cells derived from healthy subjects. Furthermore, a redox modulated p53 protein was found conformational altered in both EOSAD and ADmut B lymphocytes in comparison with control cells. This conformational altered p53 isoform, named “unfolded p53”, was recognized by the use of two specific conformational anti-p53 antibodies. Immunoprecipitation experiments, performed with the monoclonal antibodies PAb1620 (that recognizes p53wt) and PAb240 (that is direct towards unfolded p53), and followed by the immunoblotting with anti-4-hydroxynonenal (HNE) and anti- 3-nitrotyrosine (3NT) antibodies, showed a preferential increase of nitrated tyrosine residues in unfolded p53 isoform comparing to p53 wt protein, in both ADmut and EOSAD. In addition, a correlation between unfolded p53 and SOD activity was further found. Thus this study suggests that ROS/RNS contributed to change of p53 tertiary structure and that unfolded p53 can be considered as an early marker of oxidative imbalance in these patients.
Collapse
Affiliation(s)
- Laura Buizza
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy
| | - Giovanna Cenini
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy
- Sanders-Brown Centre on Aging, University of Kentucky, Lexington, Kentucky, United States of America
| | - Cristina Lanni
- Department of Experimental and Applied Pharmacology, University of Pavia, Pavia, Italy
| | | | - Chiara Prandelli
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy
| | - Stefano Govoni
- Department of Experimental and Applied Pharmacology, University of Pavia, Pavia, Italy
| | - Erica Buoso
- Department of Experimental and Applied Pharmacology, University of Pavia, Pavia, Italy
| | - Marco Racchi
- Department of Experimental and Applied Pharmacology, University of Pavia, Pavia, Italy
| | | | - Maria Styczynska
- Medical Research Centre Polish Academy of Science, Warszawa, Poland
| | - Aleksandra Szybinska
- Laboratory of Neurodegeneration, International Institute of Molecular and Cell Biology, Warszawa, Poland
| | - David Allan Butterfield
- Sanders-Brown Centre on Aging, University of Kentucky, Lexington, Kentucky, United States of America
| | - Maurizio Memo
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy
| | - Daniela Uberti
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy
- * E-mail:
| |
Collapse
|
12
|
Ferrari-Toninelli G, Bonini SA, Uberti D, Buizza L, Bettinsoli P, Poliani PL, Facchetti F, Memo M. Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol 2010; 12:1231-43. [PMID: 20716592 DOI: 10.1093/neuonc/noq101] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
High-risk neuroblastoma is a severe pediatric tumor characterized by poor prognosis. Understanding the molecular mechanisms involved in tumor development and progression is strategic for the improvement of pharmacological therapies. Notch was recently proposed as a pharmacological target for the therapy of several cancers and is emerging as a new neuroblastoma-related molecular pathway. However, the precise role played by Notch in this cancer remains to be studied extensively. Here, we show that Notch activation by the Jagged1 ligand enhances the proliferation of neuroblastoma cells, and we propose the possible use of Notch-blocking γ-secretase inhibitors (GSIs) in neuroblastoma therapy. Two different GSIs, Compound E and DAPT, were tested alone or in combination with 13-cis retinoic acid (RA) on neuroblastoma cell lines. SH-SY5Y and IMR-32 cells were chosen as paradigms of lower and higher malignancy, respectively. Used alone, GSIs induced complete cell growth arrest, promoted neuronal differentiation, and significantly reduced cell motility. The combination of GSIs and 13-cis RA resulted in the enhanced growth inhibition, differentiation, and migration of neuroblastoma cells. In summary, our data suggest that a combination of GSIs with 13-cis RA offers a therapeutic advantage over a single agent, indicating a potential novel therapy for neuroblastoma.
Collapse
Affiliation(s)
- Giulia Ferrari-Toninelli
- Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, Brescia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Ferrari-Toninelli G, Maccarinelli G, Uberti D, Buerger E, Memo M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol 2010; 10:2. [PMID: 20137065 PMCID: PMC2829550 DOI: 10.1186/1471-2210-10-2] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2009] [Accepted: 02/05/2010] [Indexed: 11/16/2022] Open
Abstract
Background Pramipexole exists as two isomers. The S(-) enantiomer is a potent D3/D2 receptor agonist and is extensively used in the management of PD. In contrast, the R(+) enantiomer is virtually devoid of any of the DA agonist effects. Very limited studies are available to characterize the pharmacological spectrum of the R(+) enantiomer of pramipexole. Results Using differentiated SH-SY5Y neuroblastoma cells as an experimental model, here we show that S(-) and R(+) pramipexole are endowed with equipotent efficacy in preventing cell death induced by H2O2 and inhibiting mitochondrial reactive oxygen species generation. Both pramipexole enantiomers prevented mitochondrial ROS generation with a potency about ten times higher then that elicited for neuroprotection. Conclusions These results support the concept of both S(-) and R(+) pramipexole enantiomers as mitochondria-targeted antioxidants and suggest that the antioxidant, neuroprotective activity of these drugs is independent of both the chiral 6-propylamino group in the pramipexole molecule and the DA receptor stimulation.
Collapse
Affiliation(s)
- Giulia Ferrari-Toninelli
- Department of Biomedical Sciences and Biotechnologies and National Institute of Neuroscience, University of Brescia, Brescia, Italy
| | | | | | | | | |
Collapse
|
14
|
Cenini G, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G, Memo M, Uberti D. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 2009. [DOI: 10.1007/s00726-009-0339-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Cenini G, Giovanna C, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G, Memo M, Uberti D. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 2009; 38:1101-6. [PMID: 19582548 DOI: 10.1007/s00726-009-0319-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2009] [Accepted: 06/19/2009] [Indexed: 11/28/2022]
Abstract
A neuropathological characteristic of Alzheimer's disease is the extracellular accumulation of amyloid beta peptide (Abeta) in neuritic plaques. Recent evidences suggested that soluble Abeta oligomers are the predominant neurotoxic species for neurons. Thus, considerable attention has been paid to discriminate the cytotoxic pathways of Abeta pre-fibrillar aggregates and mature fibrils. We showed that the mechanisms by which Abeta oligomers and fibrils generated reactive oxygen species differ in terms of site of production and kinetics, suggesting the involvement of different intra/extracellular pathways.
Collapse
Affiliation(s)
- Giovanna Cenini
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Viale Europa 11, 25124, Brescia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ferrari-Toninelli G, Bonini SA, Uberti D, Napolitano F, Stante M, Santoro F, Minopoli G, Zambrano N, Russo T, Memo M. Notch activation induces neurite remodeling and functional modifications in SH-SY5Y neuronal cells. Dev Neurobiol 2009; 69:378-91. [PMID: 19263417 DOI: 10.1002/dneu.20710] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Notch proteins are definitely recognized as key regulators of the neuronal fate during embryo development, but their function in the adult brain is still largely unknown. We have previously demonstrated that Notch pathway stimulation increases microtubules stability followed by the remodeling of neuronal morphology with neurite varicosities loss, thicker neuritis, and enlarged growth cones. Here we show that the neurite remodeling is a dynamic event, dependent on transcription and translation, and with functional implications. Exposure of differentiated human SH-SY5Y neuroblastoma cells to the Notch ligand Jagged1 induces varicosities loss all along the neurites, accompanied by the redistribution of presynaptic vesicles and the decrease in neurotransmitters release. As evaluated by time lapse digital imaging, dynamic changes in neurite morphology were rapidly reversible and dependent on the activation of the Notch signaling pathway. In fact, it was prevented by the inhibition of the proteolytic gamma-secretase enzyme or the transcription machinery, and was mimicked by the transfection of the intracellular domain of Notch. One hour after treatment with Jagged1, several genes were downregulated. Many of these genes encode proteins that are known to be involved in protein synthesis. These data suggest that in adult neurons, Notch pathway activates a transcriptional program that regulates the equilibrium between varicosities formation and varicosities loss in the neuronal presynaptic compartment involving the expression and redistribution of both structural and functional proteins.
Collapse
Affiliation(s)
- Giulia Ferrari-Toninelli
- Department of Biomedical Sciences and Biotechnologies, and National Institute of Neuroscience - Italy, University of Brescia, Brescia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ferrari-Toninelli G, Bonini SA, Cenini G, Maccarinelli G, Grilli M, Uberti D, Memo M. Dopamine receptor agonists for protection and repair in Parkinson's disease. Curr Top Med Chem 2008; 8:1089-99. [PMID: 18691134 DOI: 10.2174/156802608785161402] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinson's disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinson's disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinson's disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Collapse
|
18
|
Ferrari-Toninelli G, Bonini SA, Bettinsoli P, Uberti D, Memo M. Microtubule stabilizing effect of notch activation in primary cortical neurons. Neuroscience 2008; 154:946-52. [PMID: 18495362 DOI: 10.1016/j.neuroscience.2008.04.025] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2008] [Accepted: 04/10/2008] [Indexed: 01/08/2023]
Abstract
The appropriate level of microtubule stability is fundamental in neurons to assure correct polarity, migration, vesicles transport and to prevent axonal degeneration. In the present study, we have identified Notch pathway as an endogenous microtubule stabilizer. Stimulation of Notch receptors by exposure of mouse cortical neurons to the Notch ligand Jagged1 resulted in increased microtubule stability, as measured by using antibodies against post-translationally modified alpha tubulin, and changes in axonal morphology and branching, with varicosity loss, thicker neurites and enlarged growth cones. Similar effects were found after exposure of the cells to different doses of Taxol. However, contrary to Taxol, Jagged1 induced downregulation of the microtubule severing protein Spastin. We suggest that a fine-tuned manipulation of Notch signaling may represent a novel approach to modulate neuronal cytoskeleton plasticity.
Collapse
Affiliation(s)
- G Ferrari-Toninelli
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, viale Europa, 11, 25123 Brescia, Italy
| | | | | | | | | |
Collapse
|
19
|
Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. Eur J Pharmacol 2007; 569:194-6. [PMID: 17572405 DOI: 10.1016/j.ejphar.2007.05.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2007] [Revised: 04/26/2007] [Accepted: 05/03/2007] [Indexed: 11/25/2022]
Abstract
Here we demonstrate that pramipexole, an antiparkinsonian dopamine receptor agonist drug, exerts neuroprotective effects against beta-amyloid neurotoxicity. Using a specific protocol to test individually oligomers, fibrils, or unaggregated amyloid beta-peptide, we found pramipexole able to protect cells against oligomers and fibrils. Unaggregated amyloid beta-peptide was found unable to cause cell death. Fibrils and oligomers were also found to produce elevated amount of free radicals, and this effect was prevented by pramipexole. We propose pramipexole may become in the future a coadjuvant in the treatment of neuropathologies, besides Parkinson's disease, where amyloid beta-peptide-mediated oxidative injury exerts a relevant role.
Collapse
Affiliation(s)
- Daniela Uberti
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Viale Europa 11, 25124 Brescia, Italy
| | | | | | | | | | | |
Collapse
|
20
|
Uberti D, Cenini G, Olivari L, Ferrari-Toninelli G, Porrello E, Cecchi C, Pensalfini A, Pensafini A, Liguri G, Govoni S, Racchi M, Maurizio M. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem 2007; 103:322-33. [PMID: 17608641 DOI: 10.1111/j.1471-4159.2007.04757.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Here we show that human embryonic kidney (HEK) cells stably transfected with amyloid precursor protein (HEK-APP), expressed a conformational mutant-like and transcriptionally inactive p53 isoform, and turned out to be less sensitive to the cytotoxin doxorubicin in comparison with untransfected cells. Treatment of HEK-APP cells with gamma- and beta-secretase inhibitors prevented generation of unfolded, mutant-like p53 isoform and made the cells vulnerable to doxorubicin as untransfected cells. Changes in p53 conformational state and reduced sensitivity to doxorubicin were also found in untransfected HEK cells after exposure to nanomolar concentrations of beta-amyloid (Abeta) and these effects were antagonized by vitamin E. The modulator effects of Abeta on p53 conformational state were, at least in part, due to the intracellular peptides as (i) treatment of HEK-APP cells with an antibody that sequestered extracellular Abeta did not modify the capability of the cells to express the mutant-like p53 isoform; (ii) in the presence of 1% serum exogenous Abeta peptide crossed the plasma membrane, as demonstrated by confocal analysis and ELISA, and induced p53 conformational change; and (iii) in the presence of 10% serum Abeta did not enter the cells and consequently did not influence the p53 conformational state.
Collapse
Affiliation(s)
- Daniela Uberti
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Bonini SA, Memo M. Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action. Neurochem Res 2007; 32:1726-9. [PMID: 17486445 DOI: 10.1007/s11064-007-9350-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2007] [Accepted: 04/03/2007] [Indexed: 12/31/2022]
Abstract
Dopaminergic agonists have been usually used as adjunctive therapy for the cure of Parkinson's disease (PD). It is generally believed that treatment with these drugs is symptomatic rather then curative and does not stop or delay the progression of neuronal degeneration. However, several DA agonists of the DA D2-receptor family (including D2, D3 and D4-subtypes) have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental PD models. Here we summarize some recent data from our and other groups underlining the wide pharmacological spectrum of DA agonists currently used for treating PD patients. In particular, the mechanism of action of different DA agonists does not appear to be restricted to the stimulation of selective DA receptor subtypes being these drugs endowed with intrinsic, independent, and peculiar antioxidant effects. This activity may represent an additional pharmacological property contributing to their clinical efficacy in PD.
Collapse
Affiliation(s)
- Daniela Uberti
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Viale Europa 11, Brescia, 25124, Italy
| | | | | | | | | | | |
Collapse
|
22
|
Uberti D, Ferrari-Toninelli G, Bonini SA, Sarnico I, Benarese M, Pizzi M, Benussi L, Ghidoni R, Binetti G, Spano P, Facchetti F, Memo M. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology 2007; 32:872-80. [PMID: 16936710 DOI: 10.1038/sj.npp.1301185] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
We originally suggested that inhibition of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) death pathway could be taken into consideration as a potential therapeutic strategy for Alzheimer's disease (AD). However, because the critical role of TRAIL in immune surveillance, the neutralization of TRAIL protein by an antibody to prevent its binding to death receptors is definitely a risky approach. Here, we demonstrated that the blockade of the TRAIL death receptor DR5 with a specific antibody completely prevented amyloid beta peptide (A beta) neurotoxicity in both neuronal cell line and primary cortical neurons. DR5 was demonstrated to be a key factor in TRAIL death pathway. In fact, whereas TRAIL expression was enhanced dose-dependently by concentrations of beta amyloid ranging from 10 nM to 1 microM, only the highest toxic dose of A beta (25 microM) induced the increased expression of DR5 and neuronal cell death. In addition, the increased expression of DR5 receptor after beta amyloid treatment was sustained by p53 transcriptional activity, as demonstrated by the data showing that the p53 inhibitor Pifithrin alpha prevented both beta amyloid-induced DR5 induction and cell death. These data suggest a sequential activation of p53 and DR5 upon beta amyloid exposure. Further insight into the key role of DR5 in AD was suggested by data showing a significant increase of DR5 receptor in cortical slices of AD brain. Thus, these findings may give intracellular TRAIL pathway a role in AD pathophysiology, making DR5 receptor a possible candidate as a pharmacological target.
Collapse
Affiliation(s)
- Daniela Uberti
- Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Poliani PL, Mitola S, Ravanini M, Ferrari-Toninelli G, D'Ippolito C, Notarangelo LD, Bercich L, Wagener C, Memo M, Presta M, Facchetti F. CEACAM1/VEGF cross‐talk during neuroblastic tumour differentiation. J Pathol 2007; 211:541-549. [PMID: 17310502 DOI: 10.1002/path.2135] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The role of angiogenesis in tumour progression is a major subject in modern oncology and a correlation between angiogenesis and poor outcome has been demonstrated for human neuroblastomas. However, the role of angiogenesis in the maturation phase of neuroblastic tumours has never been considered. Human carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a potent pro-angiogenic factor and mediator of vascular endothelial growth factor (VEGF)-induced angiogenesis, plays a crucial role during the activation phase of angiogenesis and it has been shown to be expressed in the microvessels of the developing central nervous system as well as in newly formed immature blood vessels in many different tumours and under physiological conditions. The present study has investigated the role of CEACAM1/VEGF-mediated angiogenesis across the whole spectrum of neuroblastic tumours, from undifferentiated to fully differentiated mature ganglioneuromas. CEACAM1 is peculiarly expressed in the microvessels of areas of active tumour maturation among differentiating neuroblastic/ganglion cells, whereas it is completely absent in the vessels of poorly differentiated/undifferentiated as well as in entirely mature Schwannian-rich areas. Interestingly, VEGF expression has been found in differentiating neuroblastic/ganglion cells adjacent to CEACAM1-positive microvessels. In keeping with these observations, VEGF expression was found in human neuroblastoma SH-SY5Y cells during differentiation after retinoic acid treatment. Moreover, conditioned medium from SH-SY5Y cells collected at different stages of differentiation induced progressive in vitro up-regulation of CEACAM1 expression in human umbilical vein endothelial cells (HUVECs) that was abrogated by the specific VEGF receptor-2/KDR inhibitor SU5416. Taken together, these data point to a role for CEACAM1/VEGF cross-talk during the maturation phase of neuroblastic tumours. This may mimic physiological events leading to maturation of the vasculature in the developing normal central nervous system. On the other hand, in poorly differentiated/undifferentiated lesions, VEGF-sustained angiogenesis does not reproduce physiological steps, but rather is associated with tumour aggressiveness and may involve other molecular pathways.
Collapse
Affiliation(s)
- P L Poliani
- Department of Pathology, University of Brescia, Brescia, Italy
| | - S Mitola
- Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - M Ravanini
- Department of Pathology, University of Brescia, Brescia, Italy
| | - G Ferrari-Toninelli
- Unit of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - C D'Ippolito
- Department of Paediatrics, University of Brescia, Brescia, Italy
| | - L D Notarangelo
- Department of Paediatrics, University of Brescia, Brescia, Italy
| | - L Bercich
- Department of Pathology, University of Brescia, Brescia, Italy
| | - C Wagener
- Department of Clinical Chemistry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - M Memo
- Unit of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - M Presta
- Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - F Facchetti
- Department of Pathology, University of Brescia, Brescia, Italy
| |
Collapse
|
24
|
Francisconi S, Codenotti M, Ferrari-Toninelli G, Uberti D, Memo M. Preservation of DNA integrity and neuronal degeneration. ACTA ACUST UNITED AC 2005; 48:347-51. [PMID: 15850673 DOI: 10.1016/j.brainresrev.2004.12.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2004] [Accepted: 12/09/2004] [Indexed: 10/25/2022]
Abstract
The mismatch repair system (MMR) is an important member of the DNA checkpoint, that includes a number of protein deputed to control genomic stability through cell cycle arrest, DNA repair, and apoptosis. Here we summarize some recent data from our and other groups underlining the contribution to neurodegeneration of MSH2, perhaps the most relevant component of the MMR system. These data suggest that this protein participates not only in the cancer prevention machinery for the body but also in neurodegenerative processes.
Collapse
Affiliation(s)
- Simona Francisconi
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Medical School, Italy
| | | | | | | | | |
Collapse
|
25
|
Ferrari-Toninelli G, Paccioretti S, Francisconi S, Uberti D, Memo M. TorsinA negatively controls neurite outgrowth of SH-SY5Y human neuronal cell line. Brain Res 2004; 1012:75-81. [PMID: 15158163 DOI: 10.1016/j.brainres.2004.02.080] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/19/2004] [Indexed: 01/20/2023]
Abstract
Early onset generalized dystonia is a severe form of primary dystonia linked to a mutation of the DYT1(TOR1A) gene on chromosome 9q34. DYT1 gene codifies for human torsinA, an AAA+ ATPase associated with the membranes of endoplasmic reticulum (ER) and the synaptic vesicles and proposed to be involved in trafficking of tubular-vesicular membrane through neuronal processes. In this study, the presence and the intracellular distribution of torsinA protein in SH-SY5Y neuroblastoma cells were evaluated by immunofluorescence and Western blot analysis following differentiation with retinoic acid and BDNF. Protein expression was then inhibited by transient antisense transfection and the possible effect on neurite outgrowth was observed. In SH-SY5Y cells torsinA, with an apparent MW of 38 kDa, is endogenously present and distributed, with a punctate pattern, in the cytosol and along the neurites. The protein showed high intensity of immunoreactivity in the neurite varicosities and was partially co-localized with vesicles markers. Terminally differentiated cells showed an increase of protein expression. Oligonucleotide antisense treatment induced a significant response to differentiating stimuli, lead to sprouting of longer neurites and increase in growth cone areas. A relationship between torsinA and tau protein, which is involved in axon elongation and establishment of neuronal polarity, was demonstrated by co-immunoprecipitation experiments. These findings suggest that torsinA, throughout the interaction with microtubule associated proteins, may contribute to control neurite outgrowth and could be involved in maintaining cell polarity.
Collapse
Affiliation(s)
- Giulia Ferrari-Toninelli
- Department of Biomedical Sciences and Biotechnologies, University of Brescia, Viale Europa 11, 25123 Brescia, Italy
| | | | | | | | | |
Collapse
|
26
|
Belloni M, Uberti D, Rizzini C, Ferrari-Toninelli G, Rizzonelli P, Jiricny J, Spano P, Memo M. Distribution and kainate-mediated induction of the DNA mismatch repair protein MSH2 in rat brain. Neuroscience 2000; 94:1323-31. [PMID: 10625070 DOI: 10.1016/s0306-4522(99)00380-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
DNA repair is one of the most essential systems for maintaining the inherited nucleotide sequence of genomic DNA over time. Repair of DNA damage would be particularly important in neurons, because these cells are among the longest-living cells in the body. MSH2 is one of the proteins which are involved in the recognition and repair of a specific type of DNA damage that is characterized by pair mismatches. We studied the distribution of MSH2 in rat brain by immunohistochemical analysis. We found the level of MSH2 expression in rat brain to be clearly heterogeneous. The highest intensity of staining was found in the pyramidal neurons of the hippocampus and in the entorhinal and frontoparietal cortices. Positive cells were observed in the substantia nigra pars compacta, in cerebellar granular and Purkinje cells, and in the motor neurons of the spinal cord. We investigated the possible modulation of MSH2 expression after injection of kainate. Systemic administration of kainate induces various behavioural alterations and a typical pattern of neuropathology, with cell death in the hippocampal pyramidal neurons of the CA3/CA4 fields. Kainate injection also resulted in a marked, dose-dependent increase of MSH2 immunoreactivity in the hippocampal neurons of the CA3/CA4 fields. The effect was specific, since no changes in immunoreactivity were detected in the dentate gyrus nor in other brain areas. In summary, our data suggest that a mismatch DNA repair system, of which MSH2 protein is a representative component, is heterogeneously expressed in the rat brain and specifically induced by an experimental paradigm of excitotoxicity.
Collapse
Affiliation(s)
- M Belloni
- Department of Biomedical Sciences and Biotechnologies, School of Medicine, University of Brescia, Italy
| | | | | | | | | | | | | | | |
Collapse
|